The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1694
Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease
Two cell-based gene therapies – exagamglogene autotemcel (Casgevy – Vertex) and lovotibeglogene autotemcel (Lyfgenia – Bluebird Bio) – have been approved by the FDA for treatment of sickle cell disease in patients ≥12 years old with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease
Article code: 1694a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.